Alzheimer’s disease

Verubecestat linked to worse outcomes among patients with prodromal Alzheimer’s Disease compared to placebo

1. Verubecestat, an orally administered beta amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor , did not slow or prevent the progression of dementia among patients with prodromal Alzheimer’s disease. 2. Adverse events were more often noted in the verubecestat groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prodromal Czytaj więcej…

Alzheimer’s disease

Matter: Germs in Your Gut Are Talking to Your Brain. Scientists Want to Know What They’re Saying.

ImageCreditSean McSorley In 2014 John Cryan, a professor at University College Cork in Ireland, attended a meeting in California about Alzheimer’s disease. He wasn’t an expert on dementia. Instead, he studied the microbiome, the trillions of microbes inside the healthy human body. Dr. Cryan and other scientists were beginning to Czytaj więcej…